NCT05248256

Vertebral Marrow Attention Trial (VMAT)

Vertebral Bone Marrow in Lung Cancer Attention Trial (VMAT)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: The University of Texas Health Science Center at San Antonio · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to see whether designing radiation to spare the vertebral bone marrow can limit the rates of lymphopenia during standard of care chemoradiation therapy and in the time to count recovery in the ensuing weeks. Secondary endpoints will examine whether this leads to improved disease control whether this is predictive of improved clinical outcomes such as rates of local recurrence (LR), metastasis free survival (MFS), overall survival (OS), and progression free survival (PFS) which will be followed prospectively up to 5 years.

Conditions

• Lung Cancer

Interventions

Type	Name	Description
OTHER	Evidence-based radiation dose limitation to the vertebral bone marrow	The only intervention that will occur during the radiation treatment planning process will be the application of evidence-based radiation dose limitations to the vertebral bone marrow during treatment plan optimization in order to attempt to limit Grade 3 Lymphopenia (G3L) toxicity.

Timeline

• Start date: 2022-09-29
• Primary completion: 2024-07-12
• Completion: 2024-09-18
• First posted: 2022-02-21
• Last updated: 2024-10-30

Locations

2 sites across 1 country: United States